Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDASAN…
TARRYTOWN, NY / ACCESSWIRE / October 10, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a clinical stage biopharmaceutical company focusing on the…
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s…
Meeting to feature latest clinical findings on GA Depot and showcase commitment to improving care for people living with multiple…
BERKELEY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing…
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical…
-- Phase 3 Clinical Trials for AD109 Currently Enrolling Patients in the U.S.CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) --…
Preclinical Data Demonstrate CBX-15's Anti-Tumor Efficacy in Animal Models and Ability to Enhance Immunogenicity and Induce Immune Memory through pH-Based…
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)…
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…